retinoblastoma

KDM5-C70 是 KDM5-C49 的乙酯衍生物，是一种有效的细胞渗透性泛 KDM5 组蛋白去甲基化酶抑制剂。它在骨髓瘤细胞中具有抗增殖作用，可诱导全基因组 H3K4me3 水平升高。

BS194 是一种有效的细胞周期蛋白依赖性蛋白激酶 (CDK) 抑制剂。

TPCK 是丝氨酸蛋白酶抑制剂，通过与 HPV-18 E7 蛋白的视网膜母细胞瘤蛋白 (RB) 结合核心发生反应，并能够消除其 RB 结合能力。将它添加到培养基内，可修饰活角质形成细胞中的 E7 蛋白。

Amsilarotene (TAC101) 是口服有活性的合成类视黄醇，对视黄酸受体 α (RAR-α) 具有选择性亲和力，对 RAR-α 和 RAR-β 的 Ki=为 2.4 nM 和 400 nM。它可造成人胃癌、卵巢癌细胞及肝细胞癌的凋亡，可用于研究癌症。

A-83586C is a depsipeptide antibiotic from Streptomyces karnatakensis with potent against Gram-positive activity in vitro. A-83586C acts as a highly potent inhibitor of beta-catenin/TCF4 signaling within cancer cells, while simultaneously downregulating o

BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC50 = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC50 = 4.9 nM). In addi

Perivine (Perivin) 以视网膜母细胞瘤相关蛋白 (RbAp48) 为靶点，能够解决 RbAp48-FOG-1 复合物的不稳定性。Perivine 可用于研究阿尔茨海默病。

CDK-IN-9 (compound 24) 是一种 CDK 的有效抑制剂。CDK-IN-9 也是一种能够诱导 CDK12 和 DDB1 相互作用的分子胶， 能够作用于 CDK2 E (IC50: 4 nM) 。CDK-IN-9 能够导致细胞周期蛋白 K (cyclin K) 的多泛素化及其随后的降解。CDK-IN-9 可以利用去磷酸化视网膜母细胞瘤蛋白和RNA 聚合酶 II，进而诱导细胞凋亡 (apoptosis)。

AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4 6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activities in vitro with IC(50)s of <100 nmol L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.

AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4 6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative activities in vitro with IC(50)s of <100 nmol L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 HCl was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 HCl also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.

Schisandrol B (Besigomsin) 是华中五味子的主要活性成分，具有保肝、抗炎、抗糖尿病和抗氧化的作用。它抑制活性氧的产生，也抑制 P-糖蛋白和CYP3A 的活性。

BAY 61-3606 HCl is a cell-permeable, reversible inhibitor of spleen tyrosine kinase. BAY 61-3606 HCl can inhibit degranulation and block cytokine release from mast cells. Oral administration of BAY 61-3606 to rats was shown to suppress antigen-induced passive cutaneous anaphylactic reaction, bronchoconstriction, and bronchial edema. It can also sensitize MCF-7 breast cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis by inhibiting Cdk9. This compound has been used in a pre-clinical model to explore the feasibility of targeting Syk in the treatment of retinoblastoma.

D-erythro-Sphingosine (Erythrosphingosine) hydrochloride 是一种特异性 TRPM3活化剂。D-erythro-Sphingosine 还诱导视网膜母细胞瘤蛋白 (retinoblastoma protein) 去磷酸化。

CDK4 6-IN-15 是一种口服有效和选择性 CDK4 6抑制剂。CDK4 6-IN-15 能有效抑制癌细胞生长。CDK4 6-IN-15 将细胞周期阻滞在 G1 期，并抑制视网膜母细胞瘤肿瘤抑制蛋白 (Rb) 在 S780 位点的磷酸化和 E2 因子 (E2F) 调控的基因表达。

PAWI-2 是一种具有多重生物活性的化合物，既能激活p53，也能抑制Wnt。该化合物能抑制β3-KRAS信号传导，且此作用不依赖KRAS。PAWI-2 对TBK1的磷酸化具有选择性抑制作用，促使细胞凋亡 (Apoptosis) 通过激活caspase-3 7，并引起PARP的裂解。此外，PAWI-2 通过促进视神经素进入细胞核，导致 G2 M 停滞，并能逆转依赖于整合素β3的KRAS的人类胰腺癌干细胞 (hPCSC) 的癌症干细胞特性，同时克服耐药性。在原位异种移植小鼠模型中，PAWI-2 显著抑制 hPCSC 肿瘤的生长。

Dalpiciclib (SHR-6390) 是一种高选择性、口服生物利用度和相当效力的 CDK4 和 CKD6 抑制剂，IC50 分别为 12.4 nM 和 9.9 nM。它通过抑制磷酸化 Rb 蛋白和诱导 G1 细胞周期阻滞在食管鳞状细胞癌中发挥有效的抗肿瘤活性。